BET Bromodomain Inhibitors in Triple-Negative Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [1] Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
    Shaokun Shu
    Charles Y. Lin
    Housheng Hansen He
    Robert M. Witwicki
    Doris P. Tabassum
    Justin M. Roberts
    Michalina Janiszewska
    Sung Jin Huh
    Yi Liang
    Jeremy Ryan
    Ernest Doherty
    Hisham Mohammed
    Hao Guo
    Daniel G. Stover
    Muhammad B. Ekram
    Guillermo Peluffo
    Jonathan Brown
    Clive D’Santos
    Ian E. Krop
    Deborah Dillon
    Michael McKeown
    Christopher Ott
    Jun Qi
    Min Ni
    Prakash K. Rao
    Melissa Duarte
    Shwu-Yuan Wu
    Cheng-Ming Chiang
    Lars Anders
    Richard A. Young
    Eric P. Winer
    Antony Letai
    William T. Barry
    Jason S. Carroll
    Henry W. Long
    Myles Brown
    X. Shirley Liu
    Clifford A. Meyer
    James E. Bradner
    Kornelia Polyak
    Nature, 2016, 529 : 413 - 417
  • [2] Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
    Shu, Shaokun
    Lin, Charles Y.
    He, Housheng Hansen
    Witwicki, Robert M.
    Tabassum, Doris P.
    Roberts, Justin M.
    Janiszewska, Michalina
    Huh, Sung Jin
    Liang, Yi
    Ryan, Jeremy
    Doherty, Ernest
    Mohammed, Hisham
    Guo, Hao
    Stover, Daniel G.
    Ekram, Muhammad B.
    Peluffo, Guillermo
    Brown, Jonathan
    D'Santos, Clive
    Krop, Ian E.
    Dillon, Deborah
    McKeown, Michael
    Ott, Christopher
    Qi, Jun
    Ni, Min
    Rao, Prakash K.
    Duarte, Melissa
    Wu, Shwu-Yuan
    Chiang, Cheng-Ming
    Anders, Lars
    Young, Richard A.
    Winer, Eric P.
    Letai, Antony
    Barry, William T.
    Carroll, Jason S.
    Long, Henry W.
    Brown, Myles
    Liu, X. Shirley
    Meyer, Clifford A.
    Bradner, James E.
    Polyak, Kornelia
    NATURE, 2016, 529 (7586) : 413 - +
  • [3] Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
    Shu, Shaokun
    Wu, Hua-Jun
    Ge, Jennifer Y.
    Zeid, Rhamy
    Harris, Isaac S.
    Jovanovic, Bojana
    Murphy, Katherine
    Wang, Binbin
    Qiu, Xintao
    Endress, Jennifer E.
    Reyes, Jaime
    Lim, Klothilda
    Font-Tello, Alba
    Syamala, Sudeepa
    Xiao, Tengfei
    Chilamakuri, Chandra Sekhar Reddy
    Papachristou, Evangelia K.
    D'Santos, Clive
    Anand, Jayati
    Hinohara, Kunihiko
    Li, Wei
    McDonald, Thomas O.
    Luoma, Adrienne
    Modiste, Rebecca J.
    Quang-De Nguyen
    Michel, Brittany
    Cejas, Paloma
    Kadoch, Cigall
    Jaffe, Jacob D.
    Wucherpfennig, Kai W.
    Qi, Jun
    Liu, X. Shirley
    Long, Henry
    Brown, Myles
    Carroll, Jason S.
    Brugge, Joan S.
    Bradner, James
    Michor, Franziska
    Polyak, Kornelia
    MOLECULAR CELL, 2020, 78 (06) : 1096 - +
  • [4] Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer.
    Bevill, Samantha M.
    Sciaky, Noah
    Golitz, Brian T.
    Rashid, Naim U.
    Zawistowski, Jon S.
    Johnson, Gary L.
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 80 - 80
  • [5] Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors
    Schafer, Johanna M.
    Lehmann, Brian D.
    Gonzalez-Ericsson, Paula, I
    Marshall, Clayton B.
    Beeler, J. Scott
    Redman, Lindsay N.
    Jin, Hailing
    Sanchez, Violeta
    Stubbs, Matthew C.
    Scherle, Peggy
    Johnson, Kimberly N.
    Sheng, Quanhu
    Roland, Joseph T.
    Bauer, Joshua A.
    Shyr, Yu
    Chakravarthy, Bapsi
    Mobley, Bret C.
    Hiebert, Scott W.
    Balko, Justin M.
    Sanders, Melinda E.
    Liu, Phillip C. C.
    Pietenpol, Jennifer A.
    SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (534)
  • [6] In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment
    Perez-Pena, Javier
    Serrano-Heras, Gemma
    Carlos Montero, Juan
    Corrales-Sanchez, Veronica
    Pandiella, Atanasio
    Ocana, Alberto
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (08) : 1823 - 1833
  • [7] Combination treatment with bromodomain and extra-terminal motif inhibitors in triple-negative breast cancer
    Schafer, Johanna M.
    Lehmann, Brian D.
    Redman, Lindsay N.
    Liu, Phillip
    Stubbs, Matthew
    Ruggeri, Bruce
    Scherle, Peggy
    Pietenpol, Jennifer A.
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
    Bai, Longchuan
    Zhou, Bing
    Yang, Chao-Yie
    Ji, Jiao
    McEachern, Donna
    Przybranowski, Sally
    Jiang, Hui
    Hu, Jiantao
    Xu, Fuming
    Zhao, Yujun
    Liu, Liu
    Fernandez-Salas, Ester
    Xu, Jing
    Dou, Yali
    Wen, Bo
    Sun, Duxin
    Meagher, Jennifer
    Stuckey, Jeanne
    Hayes, Daniel F.
    Li, Shunqiang
    Ellis, Matthew J.
    Wang, Shaomeng
    CANCER RESEARCH, 2017, 77 (09) : 2476 - 2487
  • [9] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Geenen, Jill J. J.
    Linn, Sabine C.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    CLINICAL PHARMACOKINETICS, 2018, 57 (04) : 427 - 437
  • [10] PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
    Jill J. J. Geenen
    Sabine C. Linn
    Jos H. Beijnen
    Jan H. M. Schellens
    Clinical Pharmacokinetics, 2018, 57 : 427 - 437
12345